[
    [
        {
            "time": "",
            "original_text": "恒瑞医药正式布局PD 研发已超5亿",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "PD研发",
                    "5亿"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "恒瑞医药正式布局PD 研发已超5亿",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-05",
            "original_text": "5月北上资金净流出金额再破纪录，6月A股行情如何演绎？",
            "features": {
                "keywords": [
                    "北上资金",
                    "净流出",
                    "破纪录",
                    "A股"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "5月北上资金净流出金额再破纪录，6月A股行情如何演绎？",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "起底恒瑞医药2018年研发投入主要流向",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "2018年",
                    "研发投入",
                    "流向"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "起底恒瑞医药2018年研发投入主要流向",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "恒瑞医药新药获批 研发费用投入超5亿元",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "新药获批",
                    "研发费用",
                    "5亿元"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "恒瑞医药新药获批 研发费用投入超5亿元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-05-31",
            "original_text": "5月31日上市公司午间公告集锦",
            "features": {
                "keywords": [
                    "上市公司",
                    "午间公告",
                    "集锦"
                ],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "5月31日上市公司午间公告集锦",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "恒瑞医药(600276.SH)注射用卡瑞利珠单抗获新药证书和药品注册批件",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "卡瑞利珠单抗",
                    "新药证书",
                    "药品注册批件"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "恒瑞医药(600276.SH)注射用卡瑞利珠单抗获新药证书和药品注册批件",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 10,
                "Duration": 10,
                "Entity_Density": 10,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "original_text": "午间公告：大烨智能发行股份购买资产方案未获证监会批准",
            "features": {
                "keywords": [
                    "大烨智能",
                    "发行股份",
                    "购买资产",
                    "证监会",
                    "未批准"
                ],
                "sentiment_score": -0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "智能设备"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "午间公告：大烨智能发行股份购买资产方案未获证监会批准",
                "Correlation": 6,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "午间公告：大烨智能发行股份购买资产事项未获证监会核准 再融资异常",
            "features": {
                "keywords": [
                    "大烨智能",
                    "发行股份",
                    "购买资产",
                    "证监会",
                    "未核准",
                    "再融资异常"
                ],
                "sentiment_score": -0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "智能设备"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "午间公告：大烨智能发行股份购买资产事项未获证监会核准 再融资异常",
                "Correlation": 7,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-06",
            "original_text": "新股速递 | 嘉宏教育启动分析师路演；翰森制药预计将于6月14日挂牌上市；日照港裕廊股份6日定价，19日登陆港交所",
            "features": {
                "keywords": [
                    "嘉宏教育",
                    "翰森制药",
                    "日照港裕廊",
                    "挂牌上市",
                    "分析师路演"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "教育",
                    "医药",
                    "港口物流"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "新股速递 | 嘉宏教育启动分析师路演；翰森制药预计将于6月14日挂牌上市；日照港裕廊股份6日定价，19日登陆港交所",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "海正药业欲卖房自救 年营收破百亿为何仍净亏4.9亿？",
            "features": {
                "keywords": [
                    "海正药业",
                    "卖房自救",
                    "营收破百亿",
                    "净亏4.9亿"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "海正药业欲卖房自救 年营收破百亿为何仍净亏4.9亿？",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]